Justice Dept. Reschedules Marijuana Products to Schedule Three

Justice Department Reschedules Marijuana Products to Schedule Three: A Step Towards Bridging Federal and State Laws

The Justice Department has made a significant move by rescheduling certain marijuana products to Schedule three under federal law. This decision, signed by Acting Attorney General Todd Blanche, shifts FDA-approved drugs with marijuana and state-licensed medical products out of the strict Schedule one category. This aligns with President Trumps push to open up medical access.

The DEA is now fast-tracking a hearing in late June to consider moving all marijuana to Schedule three. This change is seen as a nod to the twenty-four states plus D.C. with recreational use and thirty-eight states running medical programs. It recognizes states have been handling this for years.

The rescheduling means these medical products will face lighter rules, like DEA registration for security and labeling, with a quick path for state operations. Schedule three covers stuff with lower abuse risk, think ketamine or Tylenol with codeine, unlike Schedule ones heroin or LSD. Everything else stays Schedule one, no full legalization.

This sets the stage for more research, better information for doctors and patients, and maybe lower taxes for legal dispensaries. The broader shift is still in play, but its a solid step towards bridging federal rules with state reality.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
[email protected]

This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].

View sources & latest updates:
https://sources.thednn.ai/aa5f5a6c02f495e6